Neoplasm Malignant Clinical Trial
Official title:
Evaluation of a Music and Interaction Intervention on Patient Distress During Whole Body Magnetic Resonance
This is a randomized controlled trial for the evaluation of the acceptability of Whole-Body-Magnetic Resonance Imaging (WB-MRI) based on music and comunication intervention compared to a standard care condition. Subjects will be randomized into two groups: the experimental group or arm that receives the music and interaction interventions, and the control group or arm that receives a standard care condition.
Status | Recruiting |
Enrollment | 200 |
Est. completion date | December 31, 2024 |
Est. primary completion date | December 31, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - Subjects who will undergo to WB-MRI for detection, staging, therapy monitoring or screening. - Acceptance and signature of informed consent. Exclusion Criteria: - Any contra-indication to MRI examination (for example, pacemaker, in the first trimester of pregnancy, metal implants, etc.). - Anxiety disorder and psychological or pharmacological treatments for anxiety |
Country | Name | City | State |
---|---|---|---|
Italy | IEO Istituto Europeo di Oncologia | Milan |
Lead Sponsor | Collaborator |
---|---|
European Institute of Oncology |
Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Acceptability of WB-MRI based on music and comunication intervention compared to a standard care condition. | Acceptability of WB-MRI based on music and comunication intervention compared to a standard care condition.
The evaluation of the acceptability of WB-MRI will be done in both groups using an ad hoc WB-MRI acceptability questionnaire created to evaluate the acceptability of the WB-MRI based on of the interventions carried out |
1 week | |
Secondary | Measure the level of patient's distress pre and post WB-MRI in the two groups using Distress Thermometer (V2.2020) | Patients randomized in both groups will complete Distress Thermometer (Version 2.2020) to assess the level of distress before and after the procedure | 1 week |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01156870 -
First in Man Study of SAR566658 Administered in Patients With CA6-Positive and Refractory Solid Tumor
|
Phase 1 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Completed |
NCT01930552 -
A Phase I Study of Aflibercept Plus FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) in Chinese Patients With Advanced Solid Malignancies
|
Phase 1 | |
Completed |
NCT01657214 -
Phase I, Dose Escalation of SAR125844 in Asian Solid Tumor Patients
|
Phase 1 | |
Active, not recruiting |
NCT03911388 -
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
|
Phase 1 | |
Completed |
NCT02575781 -
A Study of SAR428926 in Patients With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT01943838 -
A Study of the Safety and Pharmacokinetics of SAR245408 Tablets in Patients With Solid Tumors or Lymphoma
|
Phase 1 | |
Completed |
NCT03324113 -
Evaluation of SAR408701 in Japanese Patients With Advanced Malignant Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06238687 -
A Study of STRO-002 in Chinese Adults With Epithelial Ovarian Cancer and Other Advanced Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT02435121 -
A Study Assessing Efficacy and Safety of SAR125844 in NSCLC Patients With MET Amplification
|
Phase 2 | |
Completed |
NCT01985191 -
A Safety and Efficacy Study of SAR405838 and Pimasertib in Cancer Patients
|
Phase 1 | |
Completed |
NCT01455532 -
A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT03491631 -
Phase I Study of SHR9146 + SHR-1210 +/- Apatinib in Patients With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04067388 -
iKnife REIMS Project
|
||
Completed |
NCT01836705 -
Effect of SAR302503 on ECG Activity in Patients With Solid Tumors
|
Phase 1 | |
Completed |
NCT01140607 -
Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment
|
Phase 1 | |
Recruiting |
NCT04495790 -
AIMS Cancer Outcomes Study
|
||
Recruiting |
NCT05714553 -
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
|
Phase 1/Phase 2 | |
Recruiting |
NCT04733469 -
EMPOWER 3: Improving Palliative Care Health Literacy and Utilization
|
N/A | |
Active, not recruiting |
NCT03845166 -
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
|
Phase 1 |